| Bioactivity | 3M-011 is a potent dual toll-like receptor TLR7/8 agonist and a cytokine inducer. 3M-011 significantly inhibits H3N2 influenza viral replication in the nasal cavity. 3M-011 is also a potent adjuvant to radiotherapy that induces local and profound systemic immune responses during radiotherapy. 3M-011 strongly has antitumor action[1][2][3]. |
| Invitro | 3M-011 (0-100 μg/mL; 24 hours; B16-F10 melanoma cells) treatment can decrease B16-F10 melanoma cell counts[1].3M-011 potentiates natural killer (NK) cells cytotoxicity[1].The NF-κB reporter is stably integrated into HEK-293 cells that are subsequently transiently transfected with human or mouse TLR7 or TLR8. With all the TLRs tested, except mouse TLR8, stimulation with 3M-011 results in a dose-dependent induction of NF-κB-controlled luciferase activity. 3M-011 in humans activates both TLR7 and TLR8, whereas in mice, 3M011 activates only TLR7 and not TLR8[1]. Cell Cytotoxicity Assay[1] Cell Line: |
| In Vivo | 3M-011 (1 mg/kg; intravenous injection; every other day with six doses; female scid/NOD mice) treatment shows antitumor effects in scid/NOD mice bearing B16-F10 cells[1].Wild-type C57BL/6 mice are injected subcutaneously with different doses of 3M-011 (0.01 mg/kg, 0.1 mg/kg, 1 mg/kg, or 10 mg/kg). 3M-011 induces a dose-dependent increase in serum concentrations of both TNF-α and IFN-α/β[1]. Animal Model: |
| Name | 3M-011 |
| CAS | 642473-62-9 |
| Formula | C18H25N5O3S |
| Molar Mass | 391.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Dumitru CD, et al. NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model. Cancer Immunol Immunother. 2009 Apr;58(4):575-87. [2]. Hammerbeck DM, et al. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats. Antiviral Res. 2007 Jan;73(1):1-11. [3]. Schölch S, et al. Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors. Oncotarget. 2015 Mar 10;6(7):4663-76. |